Literature DB >> 18059137

Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema.

Kilkil Gamze1, Hamdi Muz Mehmet, Figen Deveci, Teyfik Turgut, Fulya Ilhan, Ibrahim Ozercan.   

Abstract

Endothelin (ET) receptor antagonists have been developed to produce a reduction of ET related effects in various diseases, as well as in animal models of airway inflammation. We aimed to investigate the anti-inflammatory potential of bosentan on a rat model of emphysema. Thirty Wistar male rats were classified as control group (group 1), intratracheally (i.t.) instilled with saline, treated with vehicle solution; elastase group (group 2), i.t. instilled with porcine pancreatic elastase (PPE), treated with vehicle solution; and PPE+bosentan group (group 3), i.t. instilled with PPE, treated with bosentan. The levels of TNF-alpha, IL-1beta, IL-6, and IL-8 in bronchoalveolar lavage fluid (BALF) and lung tissue, cell counts in BALF, and histologic analysis of all groups were evaluated. Neutrophile granulocytes (NG) and alveolar macrophages (AM) were increased more in group 2 than in group 1 (P<0.001, P=0.04, respectively). Compared with group 2, neutrophil granulocyte (NG) and alveolar macrophages (AM) counts were decreased in group 3 (P<0.001). Histological examination confirmed a diffuse neutrophilic inflammation and irregular alveolar air space enlargement in group 2. Treatment with bosentan partially reduced the enlarged lung volumes. Compared with group 1, the BALF levels of TNF-alpha and IL-6, and the lung tissue levels of IL-1beta, IL-6, and IL-8 were increased in group 2 (P=0.028, P=0.005, P=0.001, P=0.019, P<0.001, respectively). The TNF-alpha and IL-8 levels of BALF (P=0.007, P=0.001, respectively), and the TNF-alpha, IL-1beta, IL-6, and the IL-8 levels of lung tissue (P=0.031, P=0.017, P=0.007, P<0.001) were decreased in group 3 compared to group 2. In conclusion, bosentan decreased the inflammatory response by reducing numbers of inflammatory cells and proinflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059137     DOI: 10.1038/emm.2007.67

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  9 in total

1.  Bosentan: a rapidly expanding role in the management of cardio-thoracic diseases.

Authors:  Shailendra Kapoor
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

Review 2.  Endothelin-1 and its role in the pathogenesis of infectious diseases.

Authors:  Brandi D Freeman; Fabiana S Machado; Herbert B Tanowitz; Mahalia S Desruisseaux
Journal:  Life Sci       Date:  2014-04-26       Impact factor: 5.037

3.  Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension.

Authors:  André P Lourenço; Francisco Vasques-Nóvoa; José Oliveira-Pinto; Dulce Fontoura; Roberto Roncon-Albuquerque; Adelino F Leite-Moreira
Journal:  Intensive Care Med       Date:  2012-02-14       Impact factor: 17.440

4.  Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure.

Authors:  Zhongwei Sun; Feng Li; Xin Zhou; Wen Wang
Journal:  J Vis Exp       Date:  2017-08-25       Impact factor: 1.355

Review 5.  Animal models of chronic obstructive pulmonary disease.

Authors:  Joanne L Wright; Manuel Cosio; Andrew Churg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-02       Impact factor: 5.464

6.  Acute Lung Injury in Response to Intratracheal Instillation of Lipopolysaccharide in an Animal Model of Emphysema Induced by Elastase.

Authors:  Maria Aparecida Esteves Rabelo; Leda Marília Fonseca Lucinda; Maycon Moura Reboredo; Lídia Maria Carneiro da Fonseca; Fernando Fonseca Reis; Thaís Fernanda Fazza; Danielle Ribeiro Brega; Flavia de Paoli; Adenilson de Souza da Fonseca; Bruno Valle Pinheiro
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

7.  The Hypolipidemic Effect of Dalbergia odorifera T. C. Chen Leaf Extract on Hyperlipidemic Rats and Its Mechanism Investigation Based on Network Pharmacology.

Authors:  Hui Mei; Huiming Hu; Yanni Lv; Guangqiang Ma; Fangrui Tang; Zhou Hong; Feng Shao
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-27       Impact factor: 2.629

8.  Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study.

Authors:  Omer Araz; Elif Demirci; Elif Yilmazel Ucar; Muhammet Calik; Didem Pulur; Adem Karaman; Muhammed Yayla; Eren Altun; Zekai Halici; Metin Akgun
Journal:  Multidiscip Respir Med       Date:  2013-12-17

9.  A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice.

Authors:  Taichi Kato; Yoshihide Mitani; Masahiro Masuya; Junko Maruyama; Hirofumi Sawada; Hiroyuki Ohashi; Yukiko Ikeyama; Shoichiro Otsuki; Noriko Yodoya; Tsutomu Shinohara; Eri Miyata; Erquan Zhang; Naoyuki Katayama; Hideto Shimpo; Kazuo Maruyama; Yoshihiro Komada; Masahiro Hirayama
Journal:  Pulm Circ       Date:  2020-05-14       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.